A favipiravir-induced angioedema and urticaria in a COVID-19 patient
Antiviral Therapy, cilt.27, sa.6, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 6
- Basım Tarihi: 2022
- Doi Numarası: 10.1177/13596535221146226
- Dergi Adı: Antiviral Therapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, EMBASE, MEDLINE
- Anahtar Kelimeler: Favipravir, angioedema, side effects
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test presented to our hospital. After examination, favipiravir and paracetamol were prescribed. She represented to the hospital with facial swelling and itchy rashes on her forearm. Angioedema and urticaria were diagnosed. Favipiravir was discontinued. Steroid and antihistaminic therapy were administered for angioedema. To our knowledge, this is the first reported case of favipiravir-induced angioedema and urticaria in Turkey.